Top Story Today
Novartis's New MS Pill Doesn't Nuke Your Immune System. It Just Turns Down the Heat.
Most MS drugs work like bouncers: they block, remove, or deplete immune cells entirely. Novartis's remibrutinib takes a different approach, dialing down the overactive enzyme (BTK) that tells immune cells to attack the brain, without wiping them out. Across two Phase 3 trials with roughly 2,000 patients, the oral pill beat teriflunomide on relapses, shrank inflammatory brain lesions, and showed hints of slowing disability progression at six months. Crucially, there were zero liver toxicity signals, a problem that has tripped up rival BTK inhibitors. Analysts project peak sales of $3 billion to $5 billion or more.
Why it matters: This is the strongest Phase 3 readout yet for a BTK inhibitor in MS, validating a new drug class that could calm neuroinflammation from inside the brain rather than just at its borders. It reshuffles a four-way competitive race with Sanofi, Roche, and Merck KGaA in a $27 billion market.
Read more →Deals and M&A
Novartis Pays $3.2 Billion to Make the IV Drip Obsolete
The deal gives Novartis access to Alteogen's ALT-B4 technology, which lets bulky biologic drugs squeeze under the skin instead of requiring an IV drip. The deal (up to $3.22 billion in milestones and royalties) signals that converting hospital infusions into at-home injections is now a top-tier strategic priority. Alteogen has now signed eight global pharma partners, with per-product deal values climbing fast.
Read more →Roche Drops $75M on a Chinese Trispecific Antibody That Hasn't Touched a Human
Roche paid $75 million upfront (up to $1.53 billion total) for SIM0660, a preclinical trispecific antibody from China's Simcere that grabs three targets to drag T cells toward rogue B cells. The deal underscores Big Pharma's continued appetite for Chinese-origin innovation; cross-border licensing from China hit $137.7 billion across 186 deals in 2025 alone, and 2026 is on pace to beat that.
Read more →Eli Lilly's $25 Billion Deal Spree Is Funding the Next Generation of Startups
Lilly has closed more than $25 billion in acquisitions this year, returning cash to over 50 venture investors. Venrock earned a 45x return on Kelonia Therapeutics alone. That capital is cycling right back into new funds and new startups, spinning the flywheel that keeps biotech company formation alive. The catch: two-thirds of the recycled money is flowing to later-stage companies, not scrappy seed rounds.
Read more →Clinical Wins and Losses
BioNTech's Personalized Cancer Vaccine Might Have Made Patients Worse
BioNTech and Genentech killed their Phase 2 mRNA cancer vaccine trial in colorectal cancer after a troubling signal: patients on the vaccine arm appeared to die at higher rates than those getting no treatment at all. The failure contrasts sharply with Moderna's recent Phase 3 win in melanoma, suggesting mRNA can fight cancer, but only when paired with checkpoint inhibitors and tested in the right tumor types.
Read more →Lupus Just Took Another TYK2 Drug to School
Alumis lost 56% of its market value after its TYK2 inhibitor missed every endpoint in a midstage lupus trial. The company is pointing to a prespecified subgroup that responded well, but investors aren't buying it. The miss adds to a pattern: TYK2 inhibitors shine in psoriasis but keep struggling against the multi-organ complexity of lupus.
Read more →Regeneron's New Drug Blocked 90% of Rogue Bone Growth in a Brutal Rare Disease
The FDA approved Regeneron's Pasatru for FOP, a disease that slowly turns soft tissue into a second skeleton. Phase 3 data showed a 90-94% reduction in new bone lesions and over 99% reduction in rogue bone volume versus placebo. Priced at $1.4 million per year, it gives Ipsen's struggling Sohonos franchise its first serious competitor.
Read more →Industry Shifts
The U.S. Government Wants to 3D-Print Your RNA Medicine at the Hospital
ARPA-H awarded $125 million to teams building automated, point-of-care RNA drug factories. The goal: compress personalized RNA manufacturing from a nine-week ordeal into something closer to on-demand. If even one team delivers, it could make rare disease treatments commercially viable and turn pandemic response from months into days.
Read more →Arsenal Bio Fired Most of Its Staff to Bet on a Technology That Barely Exists
Arsenal Biosciences cut 99 employees, killed its clinical programs, and pivoted entirely from ex vivo to in vivo CAR-T, which reprograms immune cells inside the body instead of in a factory. Backed by $630 million from investors including SoftBank and BMS, the move is a loud insider signal that the current CAR-T manufacturing model has a ceiling.
Read more →Novo's Weight-Loss Pill Hits German Pharmacies. Patients Are Paying Cash.
Oral Wegovy launched in Germany on September 1, making it the first EU market with a weight-loss pill rivaling the famous injection (13.6% body weight loss in trials). The twist: German insurance won't cover it, so patients pay roughly 170 to 280 euros monthly out of pocket. It's a live experiment in whether the oral GLP-1 revolution needs insurance to take off.
Read more →A Phage Therapy Biotech Just Became a Defense Company. Yes, Really.
BiomX, down to $1.2 million in cash after its phage therapy trials collapsed, is rebranding as Tessera Defense and Homeland Security Inc. The ticker changes from PHGE to HLSQ on September 11. With a steep stock decline in the high 90% range and zero approved phage therapies industrywide, the pivot is part survival move, part cautionary tale about commercializing phage science.
Read more →